Eli Lilly & Co. (LLY)

79.75
NYSE : Health Technology
Prev Close 79.75
Day Low/High 0.00 / 0.00
52 Wk Low/High 73.69 / 89.09
Avg Volume 4.84M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 87.55B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (2.66%)

Latest News

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Weekly Roundup

The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Adding to Kohl's on Weakness

Kohl's is a company with 100% of revenue coming from the United States.

Buying More Lilly

We are picking up LLY shares into weakness, below our basis in the process.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.

Weekly Roundup

Fears of a trade war and a Fed rate hike marked a volatile week.

Eli Lilly: Is the Coast Now Clear for the Bulls?

Eli Lilly: Is the Coast Now Clear for the Bulls?

Traders should stay alert and nimble with LLY stock.

Qualcomm Ex-Chairman's Leveraged Buyout Bid a Real Long Shot

Qualcomm Ex-Chairman's Leveraged Buyout Bid a Real Long Shot

Former Executive Chairman Paul Jacobs is considering a leveraged buyout, which would be incredibly expensive and face tough regulatory scrutiny.

Weekly Roundup

White House gets new economic adviser.

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.

Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)

Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)

Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.

Eli Lilly Pleased With Uptake for Breast Cancer Drug Verzenio, Says Exec

Eli Lilly Pleased With Uptake for Breast Cancer Drug Verzenio, Says Exec

The Indianapolis-based drugmaker launched Verzenio in October.

Weekly Roundup

Trump signs tariffs...markets recover

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, APU, EBR, FNCB, TROW Downgrades: BSX, HLF, IROQ, KR, KWR, LABL, LLY, NX Initiations: AQN Read on to get TheStreet Quant Ratings' detailed report:

Boehringer Ingelheim And Lilly Expand Heart Failure Program For Jardiance® With New Exercise Capacity Trials

Boehringer Ingelheim And Lilly Expand Heart Failure Program For Jardiance® With New Exercise Capacity Trials

EMPERIAL clinical trials will evaluate the effect of Jardiance (empagliflozin) on exercise ability and heart failure symptoms in people with chronic heart failure

Weekly Roundup

Volatility picked up this week due to news from Washington.

Eli Lilly Needs to Prove It Can Overcome Resistance Above $82

Eli Lilly Needs to Prove It Can Overcome Resistance Above $82

The price of LLY has climbed and the bearish price target on the Point and Figure chart is off the table.

Weekly Roundup

We added one FANG name and trimmed others as markets remained volatility.

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Consider this LLY bullishly biased vertical call spread expiring in June.

Last Week's Portfolio Updates

Initiations/Exits, Price Target Updates and Ratings Changes are all here.

Survey Reveals Many People With Migraine Live With Pain Nearly Half Of Every Month

Survey Reveals Many People With Migraine Live With Pain Nearly Half Of Every Month

- Migraine Impact Report highlights physical, social and economic challenges of migraine -

AAD 2018: Treatment With Lilly's Taltz® (ixekizumab) Resulted In Improvement In Impact Of Genital Psoriasis On Sexual Activity

AAD 2018: Treatment With Lilly's Taltz® (ixekizumab) Resulted In Improvement In Impact Of Genital Psoriasis On Sexual Activity

- Reductions in the impact of genital psoriasis on sexual activity seen as early as one week -

Weekly Roundup

Markets rebound this week.

TheStreet Quant Rating: C (Hold)